BRIEF published on 11/28/2024 at 18:45, 1 year 11 months ago Medincell annonce une vidéoconférence pour ses résultats semestriels Résultats Semestriels Schizophrénie Medincell Videoconference Technologie BEPO
BRIEF published on 11/28/2024 at 18:45, 1 year 11 months ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
PRESS RELEASE published on 11/28/2024 at 18:40, 1 year 11 months ago Informations privilégiées / Autres communiqués Medincell tiendra une vidéoconférence pour présenter ses résultats financiers semestriels le mardi 10 décembre 2024. La société développe des médicaments injectables à action prolongée dans divers domaines thérapeutiques Résultats Financiers Medincell Médicaments Injectables Videoconference Technologie BEPO
BRIEF published on 11/22/2024 at 18:05, 1 year 11 months ago MedinCell : Mise à jour du capital social et des droits de vote Droits De Vote Euronext Capital Social Actions Medincell
BRIEF published on 11/22/2024 at 18:05, 1 year 11 months ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
PRESS RELEASE published on 11/22/2024 at 18:00, 1 year 11 months ago Informations privilégiées / Autres communiqués Euronext informe sur les droits de vote et le capital social de MedinCell. MedinCell, biopharmaceutique en France, développe des médicaments injectables à action prolongée Droits De Vote Euronext Capital Social Biopharmaceutique Medincell
BRIEF published on 11/06/2024 at 13:47, 1 year 11 months ago Medincell : Revenus 2024 à la hausse et avancée clinique significative Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
BRIEF published on 11/06/2024 at 13:47, 1 year 11 months ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 11 months ago Informations privilégiées / Autres communiqués Medincell relève ses prévisions de revenus UZEDY® de 25% et franchit une étape majeure dans l'essai clinique de l'Olanzapine LAI. Tous les détails dans le communiqué de presse de Teva pour le troisième trimestre 2024 Revenus Essai Clinique Medincell Teva UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 11 months ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
Published on 10/30/2026 at 23:35, 3 hours 59 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 4 hours 4 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 6 hours 47 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 8 hours 34 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 12 hours 4 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 4 hours 45 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 8 hours 56 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 4 hours 34 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 4 hours 34 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
